Showing 19,841 - 19,860 results of 134,975 for search '(( 2 c decrease ) OR ( 5 ((point decrease) OR (((a decrease) OR (mean decrease)))) ))', query time: 1.94s Refine Results
  1. 19841

    Distributed delay can either increase of decrease pulse duration in an incoherent feedforward loop. by Krešimir Josić (155006)

    Published 2013
    “…This time is simply the difference of the longer path duration () and the shorter path duration (). (C) <i>Bottom</i>: Depending on the thresholds , , and , the expected pulse duration can either increase or decrease as a function of the delay variability. …”
  2. 19842
  3. 19843
  4. 19844
  5. 19845
  6. 19846
  7. 19847
  8. 19848
  9. 19849
  10. 19850
  11. 19851

    <i>Ssdp</i> overexpression causes abnormalities in mitochondrial morphology and dynamics. by Safa Salim (9186786)

    Published 2023
    “…(B) Mitochondrial area in SEZ (Cohen’s d = −2.0 [95 CI −2.84, −1.13], <i>p</i> < 0.0001, <i>n</i> = 10) and SLP (Cohen’s d = −3.8 [95 CI −5.39, −2.55], <i>p</i> < 0.0001, <i>n</i> = 10), and circularity in SEZ (Cohen’s d = −2.6 [95 CI −3.57, −1.65], <i>p</i> < 0.0001, <i>n</i> = 10) and SLP (Cohen’s d = −2.6 [95 CI −3.4, −1.6], <i>p</i> < 0.0001, <i>n</i> = 10) are significantly decreased, while length in SEZ (Cohen’s d = 1.5 [95 CI 0.822, 2.19], <i>p</i> = 8.0 × 10<sup>−04</sup>, <i>n</i> = 9–10) and SLP (Cohen’s d = 2.1 [95 CI 1.29, 2.86], <i>p</i> < 0.0001, <i>n</i> = 10) is significantly increased in Ssdp<sup>[2082-G4]</sup> in comparison to Elav controls. …”
  12. 19852
  13. 19853
  14. 19854

    Long-Term Clinical Outcome of Internal Globus Pallidus Deep Brain Stimulation for Dystonia by Hye Ran Park (844306)

    Published 2016
    “…The mean disability score was also decreased over time, from 11.54 points preoperatively to 8.26 points at 60-month follow up, despite no statistical significance (N = 19, <i>P</i> = 0.073). …”
  15. 19855
  16. 19856
  17. 19857
  18. 19858

    Effects of telomestatin on Topo III signals and Topo III/TRF2/BLM protein levels in MRC5-V1/YFP-Topo III cells. by Nassima Temime-Smaali (260017)

    Published 2009
    “…<p>A, Representative images of untreated MRC5-V1/YFP-Topo III cells and cells treated with 2 µM telomestatin for 48 h; Topo III was detected by fluorescence of YFP-tagged Topo III (green) or by immunofluorescence using D6 antibody (red). …”
  19. 19859
  20. 19860

    Homologs of 16p12.1 genes contribute towards neurodevelopmental defects through weak genetic interactions and combined independent effects. by Lucilla Pizzo (2735491)

    Published 2021
    “…Scale bar represents 100 μm. (<b>C</b>) Simultaneous knockdown of <i>UQCR-C2</i><sup><i>GD11238</i></sup> with <i>CG14182</i><sup><i>GD2738</i></sup> (n = 18, two-tailed Mann-Whitney with Benjamini-Hochberg correction, *p = 0.002) or <i>Sin</i><sup><i>GD7027</i></sup> (n = 19, *p = 0.023) led to a significant enhancement in the eye phenotype (measured using <i>Flynotyper</i> scores) compared to knockdown of <i>UQCR-C2</i><sup><i>GD11238</i></sup> alone. …”